A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Clinical trial NCT01629667 · TERMINATED

Trial details

NCT number: NCT01629667
Sponsor: MedImmune LLC
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Idiopathic Pulmonary Fibrosis

Start date: 2012-10-01
Primary completion: 2015-05-01
Enrollment: 409

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.